Loss of circadian clock gene expression is associated with tumor progression in breast cancer

Cristina Cadenas*, Leonie Van De Sandt, Karolina Edlund, Miriam Lohr, Birte Hellwig, Rosemarie Marchan, Marcus Schmidt, Jörg Rahnenführer, Henrik Oster, Jan G. Hengstler

*Corresponding author for this work
50 Citations (Scopus)


Several studies suggest a link between circadian rhythm disturbances and tumorigenesis. However, the association between circadian clock genes and prognosis in breast cancer has not been systematically studied. Therefore, we examined the expression of 17 clock components in tumors from 766 node-negative breast cancer patients that were untreated in both neoadjuvant and adjuvant settings. In addition, their association with metastasis-free survival (MFS) and correlation to clinicopathological parameters were investigated. Aiming to estimate functionality of the clockwork, we studied clock gene expression relationships by correlation analysis. Higher expression of several clock genes (e.g., CLOCK, PER1, PER2, PER3, CRY2, NPAS2 and RORC) was found to be associated with longer MFS in univariate Cox regression analyses (HR<1 and FDR-adjusted P < 0.05). Stratification according to molecular subtype revealed prognostic relevance for PER1, PER3, CRY2 and NFIL3 in the ERC/HER2- subgroup, CLOCK and NPAS2 in the ER-/HER2- subtype, and ARNTL2 in HER2C breast cancer. In the multivariate Cox model, only PER3 (HR D 0.66; P D 0.016) and RORC (HR D 0.42; P D 0.003) were found to be associated with survival outcome independent of established clinicopathological parameters. Pairwise correlations between functionally-related clock genes (e.g., PER2-PER3 and CRY2-PER3) were stronger in ERC, HER2- and low-grade carcinomas; whereas, weaker correlation coefficients were observed in ER- and HER2C tumors, high-grade tumors and tumors that progressed to metastatic disease. In conclusion, loss of clock genes is associated with worse prognosis in breast cancer. Coordinated co-expression of clock genes, indicative of a functional circadian clock, is maintained in ERC, HER2-, low grade and non-metastasizing tumors but is compromised in more aggressive carcinomas.

Original languageEnglish
JournalCell Cycle
Issue number20
Pages (from-to)3282-3291
Number of pages10
Publication statusPublished - 15.10.2014

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Loss of circadian clock gene expression is associated with tumor progression in breast cancer'. Together they form a unique fingerprint.

Cite this